Drugs Monitor, Page 5

(18 Apr 2021) Hydroxychloroquine- chemoprophylaxis with oral HCQ was effective in young and healthy men

April 30, 2021

Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial https://doi.org/10.1016/j.ijid.2021.04.035 NCT04446104-A total of 3,037 asymptomatic participants (mean age, 33.0 years; all men) who were seronegative to SARS-CoV-2 at baseline were included in the… Continue reading "(18 Apr 2021) Hydroxychloroquine- chemoprophylaxis with oral HCQ was effective in young and healthy men"

(18 Apr 2021) Otilimab- demonstrated a substantial benefit in severe COVID patients

April 30, 2021

A Randomized Trial of Otilimab in Severe COVID-19 Pneumonia (OSCAR) https://www.medrxiv.org/content/10.1101/2021.04.14.21255475v1 NCT04376684- Overall, 806 patients were randomized (1:1); 71% of patients receiving otilimab were alive and free of respiratory failure at Day 28 versus 67% receiving placebo, although this did… Continue reading "(18 Apr 2021) Otilimab- demonstrated a substantial benefit in severe COVID patients"

(18 Apr 2021) Ivermectin- a significant protection of Ivermectin as a PrEP method of infection from SARS-CoV-2 was observed

April 30, 2021

Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers https://www.medrxiv.org/content/10.1101/2021.04.10.21255248v2 NCT04832945-The study began on June 29, 2020 and ended on July 26, 2020, where 713 active healthcare personnel were included for the analysis, of which… Continue reading "(18 Apr 2021) Ivermectin- a significant protection of Ivermectin as a PrEP method of infection from SARS-CoV-2 was observed"

(15 Apr 2021) Iota-Carrageenan- showed significant efficacy in preventing SARS-Cov-2 infection in hospital personnel

April 30, 2021

Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02) https://www.medrxiv.org/content/10.1101/2021.04.13.21255409v1 NCT04521322- A total of 394 individuals were randomly assigned… Continue reading "(15 Apr 2021) Iota-Carrageenan- showed significant efficacy in preventing SARS-Cov-2 infection in hospital personnel"

(13 Apr 2021) Corticosteroids- patients showed non-significant differences in VFD compared to IL-6R antagonists

April 30, 2021

Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and/or Corticosteroid Therapy, the INTERACT study: A Multicenter International Observational Study https://www.medrxiv.org/content/10.1101/2021.04.12.21255323v1 NCT04486521- A total of 860 patients met eligibility criteria: 589 received steroids, 170… Continue reading "(13 Apr 2021) Corticosteroids- patients showed non-significant differences in VFD compared to IL-6R antagonists"

(13 Apr 2021) Budesonide- reduced time to recovery by a median of 3 days

April 30, 2021

Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1 ISRCTN86534580- The trial opened on April 2, 2020. Randomization to inhaled budesonide began on November 27, 2020 and… Continue reading "(13 Apr 2021) Budesonide- reduced time to recovery by a median of 3 days"

(13 Apr 2021) Corticosteroids- no significant effect on the recovery time of anosmia

April 29, 2021

Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study https://doi.org/10.1016/j.amjoto.2021.103033 NCT04569825-The study was designed as a randomised, double-blind, placebo-controlled clinical trial. In total, 276 PCR-confirmed COVID-19 patients who were presented to the… Continue reading "(13 Apr 2021) Corticosteroids- no significant effect on the recovery time of anosmia"

(13 Apr 2021) Niclosamide-UNI91104, a promising candidate for inhalation and intranasal therapy against COVID-19

April 29, 2021

A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19 https://doi.org/10.1016/j.lanepe.2021.100084 NCT04576312- The trial was conducted between 29 June 2020 and 08 August 2020. Thirty-four healthy volunteers received UNI91104… Continue reading "(13 Apr 2021) Niclosamide-UNI91104, a promising candidate for inhalation and intranasal therapy against COVID-19"

(13 Apr 2021) Heparin- prophylactic doses of LMWH significantly reduced mortality

April 29, 2021

Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation https://doi.org/10.1007/s11239-021-02429-z From the initial cohort of 422 patients, 264 were enrolled. Most (n = 156, 87.7%) received standard LMWH prophylaxis during hospitalization, with no significant difference… Continue reading "(13 Apr 2021) Heparin- prophylactic doses of LMWH significantly reduced mortality"

(13 Apr 2021) Budesonide- early administration of inhaled budesonide reduced time to recovery

April 29, 2021

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial https://doi.org/10.1016/S2213-2600(21)00160-0 NCT04416399-146 participants were randomly assigned-73 to usual care and 73 to budesonide. For the per-protocol population (n=139), the primary outcome occurred in ten… Continue reading "(13 Apr 2021) Budesonide- early administration of inhaled budesonide reduced time to recovery"